ribosomal protein L35a pseudogene 2Genealiases: RPL35A_10_973 · bA571F15.2
Q-omics provides the consensus-scored RPL35AP2 profile across patient tissues and cancer cell-line models. RPL35AP2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, RPL35AP2 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, RPL35AP2 RNA expression shows 6,613 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight DLBC, THCA, and STAD as cancer lineages where RPL35AP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL35AP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL35AP2 survival associations across molecular data types. RPL35AP2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL35AP2 RNA expression–survival associations across cancer types. High RPL35AP2 expression shows unfavorable associations in DLBC, KICH, KIRC, READ and ACC, but favorable associations in LUSC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify DLBC as the clearest survival context for RPL35AP2 RNA expression.
This table summarizes RPL35AP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL35AP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL35AP2 shows lower tumor expression in THCA and BRCA and higher tumor expression in KIRP, COAD and LIHC. The THCA box plot shows higher RPL35AP2 RNA expression in normal versus tumor tissue (log2 FC = −0.150, t-test p = .004).
This table shows molecular features associated with RPL35AP2 in patient tissues and cancer cell lines. In patient samples, RPL35AP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
